

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
January 14, 2014**

**ORDER GRANTING CONFIDENTIAL TREATMENT
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

Gilead Sciences, Inc.

File No. 0-19731- CF#30517

Gilead Sciences, Inc. submitted an application under Rule 24b-2 requesting extensions of prior grants of confidential treatment for information it excluded from the Exhibits to Form 10-K filed on March 14, 2005 and a Form 10-Q filed on November 6, 2006.

Based on representations by Gilead Sciences, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit(s) will not be released to the public for the time period(s) specified:

Exhibit	to Form	Filed on	Confidential Treatment Granted
10.76	10-K	March 15, 2005	through December 17, 2017
10.2	10-Q	November 6, 2006	through December 17, 2017

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Elizabeth M. Murphy
Secretary